论文部分内容阅读
目的:探讨碳酸锂对~(131)I治疗Graves病疗效的影响。方法:采取回顾性的方法对中山市人民医院2012年1月至2015年6月用~(131)I治疗的Graves病患者资料进行分析,其中患者随机分为观察组及对照组,观察组治疗前停抗甲状腺药物7~14 d以上,并同时加服碳酸锂制剂,250 mg,3次/d,并持续~(131)I治疗后至少4周,对照组则只是治疗前停抗甲状腺药物7~14 d以上,两组病人都于治疗后1个月、3个月、6个月及12个月后复查,比较两者患者的明显症状发生率、一次性治疗愈率及遵医嘱复查率。结果:观察组与对照组的明显症状发生率、遵医嘱复查率的比较,差异具有统计学意义(P<0.05),而一次性治愈率虽有所提升,差异无统计学意义(P>0.05)。结论:碳酸锂虽然未能明显提高Graves病患者~(131)I治疗的一次性治愈率,但能改善Graves病患者~(131)I治疗后发生的与甲亢相关的症状,能提高患者遵医嘱的复查率,从而提高患者Graves病治疗期间的安全性和依从性。
Objective: To investigate the effect of lithium carbonate on the therapeutic effect of 131I treatment of Graves disease. Methods: The data of patients with Graves’ disease treated with ~ (131) I in Zhongshan People’s Hospital from January 2012 to June 2015 were retrospectively analyzed. The patients were randomly divided into observation group and control group, and observation group Before stopping anti-thyroid drugs for more than 7 to 14 days, plus lithium carbonate, 250 mg, 3 times a day for at least 4 weeks after 131I treatment, while the control group only stopped anti-thyroid drugs before treatment After 7 ~ 14 days, the two groups of patients were reviewed at 1 month, 3 months, 6 months and 12 months after treatment. The incidence of obvious symptoms, the rate of one-off treatment and the compliance with the doctor’s order were compared rate. Results: The incidences of obvious symptoms in the observation group and the control group were significantly different from those in the follow-up examination (P <0.05), while the one-time cure rate was not significantly different (P> 0.05 ). CONCLUSION: Although lithium carbonate can not significantly improve the one-time cure rate of ~ (131) I treatment in patients with Graves’ disease, it can improve the symptoms associated with hyperthyroidism after ~ (131) I treatment in patients with Graves disease, Of the review rate, thereby improving the safety of patients with Graves disease treatment and compliance.